Key result
CTO revascularization lacks a clear survival advantage in recent randomized trials, though it shows trends toward improved left ventricular function, quality of life, and freedom from fatal arrhythmia.
Why the study?
Observational data showed survival benefit with successful CTO revascularization, but recent randomized trials failed to uphold this survival advantage.
Does CTO revascularization improve survival and clinical outcomes in patients with chronic total occlusions?
Does CTO revascularization improve survival and clinical outcomes in patients with chronic total occlusions?
While earlier observational data suggested a survival benefit for CTO-PCI, recent randomized trials do not confirm this, though they suggest potential benefits in symptoms and LV function for carefully selected patients.
CTO revascularization should not target survival alone; leaves open symptomatic, LV function, and arrhythmic benefits in selected patients.
No takes yet. Share an insight, caveat, or question.
Sahu et al. (2023) conducted a review in Chronic total occlusions (CTOs). CTO revascularization (CTO-PCI) was evaluated. CTO revascularization lacks a clear survival advantage in recent randomized trials, though it shows trends toward improved left ventricular function, quality of life, and freedom from fatal arrhythmia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: